Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novo Nordisk, semaglutide dose
Novo Nordisk’s Wegovy Achieves Weight-Loss of 20.7% at Higher Dose, Study Says
Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, without experiencing an increase in side-effects.
Novo Nordisk says its obesity drug in higher dose shows 20.7% weight loss
Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the results fell short of the weight loss achieved with Eli Lilly's rival drug Zepbound,
Novo Nordisk touts 'superior' weight loss results in study of high-dose Wegovy
In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is rolling out new data on a higher-dose injection in obesity. | In the phase 3b STEP UP study,
Novo Nordisk Links High-Dose Wegovy to Increased Weight Loss in Phase III Trial
Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP trial to evaluate the effect of increasing the maximum dose to 7.2 mg. The trial randomized 1,407 adults with obesity, but not diabetes, to receive either 7.2 mg or 2.4 mg of semaglutide or placebo.
Novo Nordisk's Ozempic & Wegovy in 2027 Medicare price talks
GLP-1 weight loss drugs, Ozempic and Wegovy, will be targeted in the next round of Medicare price negotiations in 2027, along with 13 other medications. Seana Smith and Brad Smith break down the details on Morning Brief.
Wegovy at Higher Dose Achieves Greater Weight Loss in Trial
Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, without experiencing an increase in side effects.
Tripling Wegovy dosage leads to more weight loss, Novo Nordisk trial shows
Tripling the dosage of the Wegovy weight-loss drug leads to more weight loss, Novo Nordisk said Friday. The Danish drugmaker announced results from a Phase 3B trial of semaglutide at a 7.2 milligram dosage,
Novo Nordisk says its high-dose semaglutide trial shows 20.7% weight loss
Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight patients lower their weight by 20.7%.
Novo Trial Shows Bigger Dose of Wegovy Helps Shed Pounds
Novo Nordisk A/S said a bigger dose of the main ingredient in Wegovy, its top-selling weight-loss drug, helped patients shed more pounds in a trial than a standard dosage.
High-dose Wegovy leads to substantial weight loss in trial, but falls short of Zepbound
A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less than what’s been seen with Zepbound.
18h
on MSN
US targets Novo Nordisk's Ozempic and Wegovy for Medicare price talks
Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...
15h
on MSN
Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today
In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...
17h
Novo Nordisk's stock down 4% as the Feds get ready for a second round of drug price negotiations
Medicare released its next target list of 15 drugs to negotiate prices of, including Novo Nordisk's blockbuster GLP-1 drugs.
1d
Novo Nordisk, other firms meet Danish PM to discuss Trump tariff threats
Danish businesses are concerned about a possible trade conflict with the United States over Greenland, a major lobby group ...
14h
LVMH overtakes Novo Nordisk as Europe’s most valuable company
Luxury bellwether regains crown as drugmaker slips on concerns it will have to cut weight loss medication prices in US ...
BioPharma Dive
11h
Medicare will negotiate Novo’s GLP-1 drug price. Here’s what that means for Ozempic, Wegovy.
Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.
1d
Finally An Attractive Entry Point Into Novo Nordisk
Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...
Money Morning
8h
Eli Lilly Faces ‘Death Cross’ Selloff: This is the Stock's Next Target Price...
The technical picture worsened for Eli Lilly stock in December as it completed a pattern known as a “Death Cross”. This ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Popular topics
# Novo Nordisk
Related topics
United States
Ozempic
Medicare
Wegovy
Greenland
Feedback